Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma - Full Text View

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

This study has been completed.

Sponsored by:	Celgene Corporation
Information provided by:	Celgene Corporation
ClinicalTrials.gov Identifier:	NCT00055562

Purpose

Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.

Condition	Intervention	Phase
Melanoma Neoplasm Metastasis	Drug: CC 5013	Phase II Phase III

MedlinePlus related topics:

Cancer Melanoma

ChemIDplus related topics:

Lenalidomide CC 5013

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy

Further study details as provided by Celgene Corporation:

Estimated Enrollment:	274
Study Start Date:	January 2003
Estimated Study Completion Date:	December 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Understand and voluntarily sign an informed consent form.
Able to adhere to the study visit schedule and other protocol requirements.
Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy.
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug.
Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055562

Show 31 Study Locations

Sponsors and Collaborators

Celgene Corporation

More Information

Study ID Numbers:	CDC-5013-MEL-001
First Received:	March 5, 2003
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00055562
Health Authority:	United States: Food and Drug Administration

Keywords provided by Celgene Corporation:

Metastatic Melanoma

Metastatic Malignant Melanoma

Revimid

CC5013

Study placed in the following topic categories:

Neuroectodermal Tumors

Nevus, Pigmented

Neoplasms, Germ Cell and Embryonal

Lenalidomide

Neoplasm Metastasis

Neuroepithelioma

Nevus

Neuroendocrine Tumors

Melanoma

Additional relevant MeSH terms:

Neoplastic Processes

Neoplasms

Pathologic Processes

Neoplasms by Histologic Type

Antineoplastic Agents

Therapeutic Uses

Neoplasms, Nerve Tissue

Nevi and Melanomas

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 07, 2008